MicroRNA-205-5p Regulates the Chemotherapeutic Resistance of Hepatocellular Carcinoma Cells by Targeting PTEN/JNK/ANXA3 Pathway
Overview
Authors
Affiliations
Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.
A Bioinformatics-Based Approach to Discover Novel Biomarkers in Hepatocellular Carcinoma.
Shourideh A, Maddah R, Amiri B, Basharat Z, Shadpirouz M Iran J Public Health. 2024; 53(6):1332-1342.
PMID: 39430152 PMC: 11488550.
Li Q, Maierheba K Immun Inflamm Dis. 2024; 12(7):e1350.
PMID: 39023413 PMC: 11256885. DOI: 10.1002/iid3.1350.
Tavakoli Pirzaman A, Alishah A, Babajani B, Ebrahimi P, Sheikhi S, Moosaei F Technol Cancer Res Treat. 2024; 23:15330338241239188.
PMID: 38634139 PMC: 11025440. DOI: 10.1177/15330338241239188.
Xu J, Liu C, Qu K, Zhang J, Liu S, Meng F Oncol Rep. 2024; 51(4).
PMID: 38426536 PMC: 10926101. DOI: 10.3892/or.2024.8718.
Fang Y, Zhang X, Huang H, Zeng Z J Transl Med. 2023; 21(1):369.
PMID: 37286982 PMC: 10249219. DOI: 10.1186/s12967-023-04238-9.